Diabetic Nephropathies: Clinical Trials

55 trials for Diabetic Nephropathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

30 completed, 10 terminated, 9 unknown, 3 withdrawn. 55 Phase 3, 15 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 355Completed 30, Terminated 10, Unknown 9, Withdrawn 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1
Phase 215Completed 9, Unknown 5, Terminated 1

Follow Diabetic Nephropathies: new trials by email Literature Review of Diabetic Nephropathies trials Research Report on Diabetic Nephropathies

Trials (filtered) newest first · largest first

All 55 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
Dapagliflozin +Finerenone arm, Dapagliflozin arm - Diabetic Nephropathy
Phase 3Not yet recruitingChittagong Medical College882026-05-012026-05-20
SGLT2 Adjunct in T1D
Empagliflozin (EMPA), Placebo - Type 1 Diabetes, Nephropathy, Diabetic
Phase 2 / Phase 3CompletedAin Shams University862024-11-202026-05-18
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Sotagliflozin, Placebo - Diabetic Nephropathies, Kidney Failure, Chronic
Phase 3RecruitingAlessandro Doria1502024-10-312026-03-24
Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Vinpocetine, Standard Therapy, Placebo - Diabetic Kidney Disease, Diabetic Nephropathies
Phase 2 / Phase 3UnknownAin Shams University642024-07-102024-07-11
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
Empagliflozin 25 MG, Enalapril Maleate 20 mg - Diabetic Nephropathy Type 2
Phase 2 / Phase 3UnknownOmar Tarek Elfarargi2122023-03-012022-05-13
Targeting Leukotrienes in Kidney Disease
Montelukast - Diabetic Kidney Disease
Phase 3TerminatedUniversity of Colorado, Denver62022-07-012025-05-30
The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy
oral sitagliptin supplementation - Type 1 Diabetic Nephropathy
Phase 3CompletedAin Shams University462022-03-012023-11-07
SER150 vs Placebo in Diabetic Kidney Disease
SER150, Placebo - Diabetic Kidney Disease
Phase 2 / Phase 3CompletedSerodus AS202021-08-182024-06-21
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution - CKD, Diabetic Kidney Disease
Phase 3TerminatedGeisinger Clinic152021-07-232024-02-09
Possible Role of Roflumilast in Diabetic Nephropathy
Roflumilast, Placebo - Diabetic Nephropathies
Phase 3UnknownTanta University482021-03-102021-02-16
Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe
Ezetimibe 10mg, Placebo - Diabetes Mellitus, Type 2, Diabetic Kidney Disease
Phase 3UnknownSteno Diabetes Center Copenhagen602020-10-012022-01-18
Niclosamide Role in Diabetic Nephropathy
Niclosamide, Placebo oral tablet - Diabetic Nephropathies
Phase 3CompletedTanta University602020-02-012022-10-20
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
Empagliflozin 10 MG - Diabetic Nephropathies
Phase 3TerminatedSingapore General Hospital22020-01-092020-12-17
Role of Fexofenadine in Diabetic Kidney Disease
Fexofenadine Pill, Placebo oral tablet - Diabetic Kidney Disease
Phase 3CompletedTanta University602020-01-012022-05-05
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
N Acetylcysteine - Diabetic Kidney Disease, Diabetes Mellitus, Type 2
Phase 2 / Phase 3UnknownAl-Azhar University602019-10-012020-08-28
Effects of Fenofibrate Therapy in Diabetic Nephropathy
Fenofibrate - Diabetes Mellitus, Diabetic Nephropathies
Phase 3UnknownSingapore General Hospital3002019-03-082020-12-14
Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease
Astragalus Powder, Routine medical care (active comparator) - Diabetic Nephropathies, Diabetic Kidney Disease
Phase 2 / Phase 3UnknownThe University of Hong Kong1182018-07-012020-12-07
A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
Bardoxolone methyl, Placebo - Diabetic Kidney Disease
Phase 3TerminatedKyowa Kirin Co., Ltd.13232018-05-302023-09-26
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Canagliflozin, Placebo - Diabetic Nephropathy
Phase 3CompletedTanabe Pharma Corporation3082018-02-152026-01-07
Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease
Jinshuibao Capsule - Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Phase 2 / Phase 3CompletedSecond Xiangya Hospital of Central South University2022017-07-242024-01-03

Showing 20 of 55. Sign in to see all of them.

Narrower conditions

Diabetes Mellitus, Type 2 (18)  ·  Diabetes Mellitus (12)  ·  Kidney Diseases (11)  ·  Proteinuria (7)  ·  Renal Insufficiency, Chronic (7)  ·  Albuminuria (6)  ·  Diabetes Mellitus, Type 1 (5)  ·  Hypertension (4)  ·  Kidney Failure, Chronic (4)  ·  Diabetic Retinopathy (3)  ·  Cardiovascular Diseases (1)  ·  Coronary Artery Disease (1)  ·  Diabetes Complications (1)  ·  Diabetic Neuropathies (1)

Broader conditions

Endocrine System Diseases (55)  ·  Female Urogenital Diseases (55)  ·  Female Urogenital Diseases and Pregnancy Complications (55)  ·  Male Urogenital Diseases (55)  ·  Urologic Diseases (55)  ·  Diabetes Complications (54)  ·  Urogenital Diseases (54)  ·  Kidney Diseases (44)  ·  Diabetes Mellitus (43)  ·  Nutritional and Metabolic Diseases (34)  ·  Glucose Metabolism Disorders (33)  ·  Metabolic Diseases (33)  ·  Pathological Conditions, Signs and Symptoms (20)  ·  Signs and Symptoms (13)  ·  Urination Disorders (12)

Interventions

empagliflozin (4)  ·  Losartan (3)  ·  Acetylcysteine (2)  ·  Calcitriol (2)  ·  Canagliflozin (2)  ·  Fenofibrate (2)  ·  Nifedipine (2)  ·  Olmesartan Medoxomil (2)  ·  Spironolactone (2)  ·  Standard of Care (2)  ·  bardoxolone methyl (2)  ·  finerenone (2)  ·  glucuronyl glucosamine glycan sulfate (2)  ·  (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1)  ·  Allopurinol (1)

Sponsors

Ain Shams University (3)  ·  Bayer (3)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)  ·  Tanta University (3)  ·  Alessandro Doria (2)  ·  Daiichi Sankyo Co., Ltd. (2)  ·  Keryx Biopharmaceuticals (2)  ·  Shiraz University of Medical Sciences (2)  ·  Singapore General Hospital (2)  ·  The University of Hong Kong (2)  ·  AbbVie (1)  ·  Al-Azhar University (1)  ·  Biogen (1)  ·  Chittagong Medical College (1)  ·  DiaNe HCM GmbH (1)

Countries

United States (16)  ·  Australia (9)  ·  Germany (9)  ·  Japan (7)  ·  Spain (7)  ·  Canada (6)  ·  China (6)  ·  Czechia (6)  ·  Egypt (6)  ·  Hong Kong (6)  ·  Denmark (5)  ·  Netherlands (5)  ·  New Zealand (5)  ·  Poland (5)  ·  United Kingdom (5)

Top investigators

Michael Mauer, MD (2)  ·  Adriaan Kooy, MD (1)  ·  Alberto Ortiz, MD (1)  ·  Alessandro Doria, MD PhD MPH (1)  ·  Alessandro Doria, MD, PhD, MPH (1)  ·  Alex R Chang, MD, MS (1)  ·  Alicia Jenkins, Professor (1)  ·  Amin Banihashemi (1)  ·  Andreas Birkenfeld, MD (1)  ·  Anne Reutens, MD (1)  ·  Anthony Keech, Professor (1)

Results publications

PMID 33107592, PMID 37872654, PMID 40526444, PMID 33280027, PMID 33358451, PMID 36251465, PMID 36287567, PMID 36328655, PMID 36639130, PMID 36864892, PMID 36927680, PMID 37745646, PMID 38046911, PMID 38048573, PMID 38508632, PMID 38682786, PMID 38770818, PMID 39380152, PMID 40315020, PMID 40892478, PMID 41196655, PMID 41198855, PMID 41289823, PMID 41533467, PMID 41679125, PMID 41827014, PMID 42234437, PMID 20189608, PMID 21270268, PMID 21872376, PMID 21993710, PMID 22718189, PMID 23545707, PMID 24013685, PMID 24206459, PMID 26936907, PMID 27496229, PMID 27612501, PMID 29253846, PMID 29665833, PMID 29781558, PMID 30231923, PMID 30990260, PMID 30995972, PMID 31291786, PMID 31573977, PMID 31665733, PMID 31707795, PMID 32135136, PMID 32354987

NIH funding

2015 (2), 1KL2RR025015-01 (1), 2005 (1), 2014 (1), P30DK017047 (1), R01DK047112 (1), UC4DK101108-01 (1)